437 results on '"Cohen, Romain"'
Search Results
2. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
3. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
4. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
5. Actualisation des données sur le traitement néoadjuvant total de l’adénocarcinome du rectum
6. Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)
7. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
8. Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients
9. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation
10. Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study
11. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study
12. Traitements péri-opératoires des adénocarcinomes œsogastriques localisés
13. Tolérance et efficacité des inhibiteurs de points de contrôle immunitaire en monothérapie chez les patients âgés
14. Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study.
15. Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study
16. Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
17. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
18. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors
19. Les dépôts tumoraux (DT), un critère pronostique péjoratif probablement sous-estimé, à prendre en compte dans la prise en charge thérapeutique des malades atteints de cancer colique de stade III
20. Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice
21. Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey
22. Discordances entre les référentiels des collèges d’enseignants en médecine et leur impact sur les étudiants en médecine
23. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
24. Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire : l’essai de phase II GERCOR NEONIPIGA vient d’être ouvert au recrutement
25. Fusions NTRK : une nouvelle piste dans les cancers digestifs ?
26. Deficient mismatch repair/microsatellite unstable colorectal cancer: therapeutic advances and questions
27. Qu’est-ce que 2023 aura permis de changer dans nos pratiques en cancérologie ?
28. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
29. Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
30. Syndrome de Lynch : quoi de neuf ?
31. État des lieux et attentes des internes d’oncologie français concernant le post-internat et la recherche : une enquête nationale GERCOR-AERIO
32. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors
33. Traitement des cancers colorectaux par immunothérapie : aller au-delà de MSI avec la classification moléculaire (CMS) et la charge mutationnelle
34. Épidémiologie des tumeurs MSI : fréquence des tumeurs MSI en fonction de la localisation du cancer et de son stade
35. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency
36. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162–170
37. Mutations de l'ADN dans les cholangiocarcinomes : cibler IDH1 et autres mutations
38. Surprisingly High Rate of Incomplete Resection in the Control Arm
39. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study
40. Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
41. Réponse immune et cancers digestifs : implications pronostiques et thérapeutiques
42. RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
43. Personalized therapy in digestive oncology: what’s new?
44. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
45. Supplementary Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
46. Data from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
47. Supplementary Figure from PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon
48. Designing Trials for Neoadjuvant Immune Checkpoint Inhibition in Microsatellite Instability–High Localized Colorectal Cancer
49. Figure S2 from Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
50. Supplementary Data from Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.